The scientific obstacle the team faced is as much ethical as it is technical. Directly studying how environmental toxicants affect pregnant women and their developing fetuses is largely off-limits, and the alternatives have serious shortcomings. Whole placentas and villous explants preserve the organ’s biological complexity but require fresh clinical specimens and are notoriously difficult to perfuse in a controlled way. Standard cultures of placental cell lines, meanwhile, flatten the placenta’s intricate three-dimensional architecture into something too simple to reflect its real-world responses. The Penn team’s answer was to build the missing middle ground: a microphysiological system in which clinically sourced primary cells assemble themselves into a vascularized, functioning placental barrier.

The device itself is a marvel of microscale engineering. Fabricated from poly(dimethylsiloxane), it consists of an upper maternal chamber and a lower fetal chamber, separated by a thin semipermeable membrane pierced with one-micrometer pores. Into the fetal chamber the researchers injected a fibrin hydrogel seeded with placental endothelial cells and fibroblasts. Over roughly a week, the endothelial cells self-organized into a three-dimensional network of open blood vessels—a process mimicking vasculogenesis in the womb—that could be perfused with flowing media through side channels. The vessels stabilized at an average diameter of about 19.9 micrometers, closely matching the 20.3 micrometers measured in real placental villi. On the upper side of the membrane, primary cytotrophoblasts were seeded and grown into a confluent monolayer studded with microvilli, the fingerlike projections that maximize exchange surface in the native organ.

What happened next is the kind of detail that makes developmental biologists sit up. Maintained at 5 percent oxygen—matching the genuinely low-oxygen environment of the human placenta rather than the 20 percent of a standard incubator—and bathed in continuous flow, the trophoblasts spontaneously fused into a syncytium, the multinucleated cell layer that performs most of the placenta’s work in vivo. The cells shed their intercellular junctions, ramped up production of the pregnancy hormone beta-hCG, and upregulated genes associated with syncytiotrophoblast maturation, including syncytin and placental growth factor. Barrier function, measured by transepithelial electrical resistance, was significantly stronger under flow than in static conditions, and the engineered tissue transferred glucose from the maternal to the fetal compartment at a rate of 33.4 percent—squarely within the physiological range documented for perfused human placental explants.

With a validated model in hand, the researchers turned to cadmium, a metal flagged as a high-priority toxicant by environmental agencies. Humans encounter cadmium through food, contaminated water, mining, fertilizer production, fossil fuel combustion and cigarette smoke, and a recent systematic review found that cadmium exposure raises the risk of low birth weight by 21 percent and preterm birth by 32 percent. When cadmium chloride was added to the maternal flow, the engineered barrier proved markedly more resilient than a conventional Transwell culture built from the same batches of primary cells. At environmentally relevant doses between 0.1 and 10 micromolar, the trophoblast layer remained largely intact, whereas the Transwell model showed substantial cell injury even at 1 micromolar. The difference, the authors argue, reflects the protective influence of physiological flow and the hydrogel stroma, which together make the microengineered system a more faithful stand-in for the real organ.

The subtler findings may prove the most consequential. Even at 5 micromolar—a dose that caused no detectable cell death—the barrier became measurably leakier, production of beta-hCG dropped, and the tissue released elevated levels of the pro-inflammatory cytokines IL-8, IL-6, IL-1β and TNF. At just 1 micromolar, expression of the glucose transporter GLUT1 fell and maternal-to-fetal glucose transfer dropped below the physiological range, even though the barrier looked structurally pristine. In other words, cadmium can sabotage placental function long before it kills a single cell, a mode of toxicity that static cultures, which register injury at far lower doses, would misread entirely. When the team added donor-matched primary Hofbauer cells—the fetal macrophages that patrol the villous stroma—the inflammatory response intensified dramatically, with IL-1β rising 3.75-fold in the fetal compartment, and the stroma showed signs of fibroblast activation and collagen deposition reminiscent of fibrosis in pre-eclamptic placentas.

Perhaps the study’s most striking mechanistic discovery concerns the placenta’s own molecular bouncers. Gene analysis revealed that cadmium exposure upregulates a family of ATP-binding cassette transporters, including BCRP, MDR1 and MRP1, which sit on the maternal-facing surface of trophoblasts and actively pump foreign substances back into the maternal circulation. When the researchers chemically inhibited BCRP, cadmium-induced cell injury roughly doubled on the maternal side and inflammatory cytokines surged in both compartments at doses that were otherwise harmless. Genetic knockdown of BCRP told the same story: the barrier began to fail at 1 micromolar instead of 5, cytotoxicity increased, and the fetal vasculature became inflamed and leaky, even recruiting adherent neutrophils when those cells were perfused through the vessels. BCRP, one of the two most abundant efflux transporters in the human placenta, appears to be a first line of defense against cadmium—a finding that could eventually inspire strategies to bolster the placenta’s natural detoxification machinery.

The team then pushed the platform into a new application: biomarker discovery. Using untargeted metabolomics on fluid collected separately from the maternal and fetal chambers, they mapped how cadmium rewires placental metabolism in a dose-dependent fashion. Higher exposures elevated pyrimidine, asparagine and serine metabolism while suppressing folate and energy-related pathways, and the fetal compartment showed a distinctive signature of disrupted fatty acid metabolism, with drops in arachidonic acid, oleic acid and glutamate—molecules essential for fetal neural development and energy supply. Notably, several of these metabolic changes mirror signatures previously reported in human placentas from pregnancies complicated by preterm birth, gestational diabetes and fetal growth restriction, suggesting that disrupted placental metabolism may be one route by which cadmium contributes to adverse outcomes. Receiver operating characteristic analysis yielded distinct sets of candidate biomarkers for low and high exposure levels, offering a potential roadmap toward clinical tests that do not yet exist.

To guard against the possibility that their findings were artifacts of the chip, the researchers ran a parallel validation using living villous explants from term placentas, perfused in a 3D-printed chamber. The explants reproduced the key responses: dose-dependent cell injury, a surge of inflammatory cytokines at high cadmium doses, and metabolic shifts that overlapped substantially with the microengineered model—roughly 48 percent of the top altered pathways matched those seen in the maternal compartment. The convergence between a fully reconstructed tissue and the native organ lends considerable weight to the platform’s predictions. Limitations remain, as the authors candidly note: the model is a simplified snapshot that cannot capture how the placenta changes across gestation, nor the direct effects of cadmium on the developing fetus itself, and the PDMS used to build the device can absorb hydrophobic compounds, restricting its use to water-soluble toxicants.

Even so, the implications are hard to overstate. For decades, the placenta has been called the forgotten organ—remarkably complex, ethically inaccessible and poorly understood. A perfusable, primary-cell model that reproduces its barrier, vasculature, immune residents and metabolic activity gives toxicologists, clinicians and regulators a human-relevant test bed for a class of exposures that touches every pregnancy on the planet. Cadmium’s prevalence is highest in developing countries, making this as much a global health equity issue as a basic science one. If follow-up work can validate the metabolite biomarkers in real patients and identify drugs or nutrients that strengthen BCRP-mediated efflux, the tiny placenta on a chip may end up protecting pregnancies far larger than itself.

Subject of Research: A microphysiological model of the human placental barrier used to study fetal exposure to environmental metals such as cadmium during pregnancy

Article Title: A bioengineered model of human placental exposure to environmental metals during pregnancy

Article References: Fattahi, P., Younesi, M., Lee, W. D., Whang, K., Kim, S.-J., Kang, T., Aleksunes, L. M., & Huh, D. D. (2026). A bioengineered model of human placental exposure to environmental metals during pregnancy. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01801-9

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01801-9

Keywords: placenta-on-a-chip, cadmium, microfluidics, trophoblast, BCRP transporter, maternal-fetal interface, environmental toxicology, pregnancy, metabolomics, organ-on-a-chip, Hofbauer cells, prenatal exposure

The review, authored by Enoch Appiah Adu-Gyamfi and Ethan Backes of the University of Wisconsin-Stout, synthesizes decades of fragmented literature into a unified framework. The authors contend that human placentation depends on the precise differentiation of trophoblasts, the specialized cells of the outer embryo, into distinct lineages, and that this differentiation is strictly regulated by the spatio-temporal expression of key genes. E-cadherin, a 120-kilodalton transmembrane glycoprotein encoded by the CDH1 gene, sits at the center of that regulatory story. When its expression pattern goes wrong, the consequences can be severe: dysregulation is evident in placentas from pregnancies complicated by preeclampsia and fetal growth restriction, two of the most common and dangerous obstetric complications.

To understand why a single adhesion protein matters so much, it helps to grasp the scale of the construction project. After the blastocyst adheres to the uterine lining, the trophectoderm gives rise to cytotrophoblasts, mononuclear and actively proliferating cells that function as stem cells for every other trophoblast lineage. These cells follow two main routes. Along the villous pathway, cytotrophoblasts multiply and fuse with one another to form the syncytiotrophoblast, a multinucleated layer that serves as the barrier controlling physiological exchange between mother and fetus. Along the extravillous pathway, they differentiate into highly invasive extravillous trophoblasts that anchor the placenta to the uterus and remodel maternal blood vessels to feed the growing fetus.

The extravillous journey is extraordinary in its own right. Proximal column trophoblasts, which remain near the villous tree, give rise to distal column trophoblasts that migrate into the decidua and become interstitial extravillous trophoblasts. Some of these invade and open the uterine glands, ensuring a supply of nutrient-rich secretions before full maternal blood flow begins. Others form temporary plugs inside the spiral arteries, deliberately restricting blood flow to maintain the low-oxygen environment that early placental development requires. Later, as fetal demands grow, endovascular trophoblasts dismantle the muscular walls of those arteries and migrate backward up their lumens, replacing the maternal endothelial lining. The arteries lose their contractility and transform from narrow, high-resistance coils into wide, flaccid conduits capable of delivering large volumes of blood at low pressure, a system fully established by the twelfth week of gestation.

E-cadherin’s structure explains both its adhesive power and its signaling reach. Its extracellular region consists of five tandemly repeated domains that form zipper-like, calcium-dependent bonds with E-cadherin molecules on neighboring cells. Its intracellular tail anchors the protein to the actin cytoskeleton through a complex of catenin proteins, linking cell-cell adhesion directly to the cell’s mechanical and signaling machinery. Beyond holding tissue together, E-cadherin regulates apico-basal polarity, enforces contact inhibition of proliferation by sequestering beta-catenin at the membrane, and is classified as a potent tumor suppressor. When cancer cells initiate epithelial-to-mesenchymal transition, transcriptional reprogramming shuts down E-cadherin, dismantling the adhesion complex and freeing cells to detach and migrate. Placental biology, the review argues, co-opts this same machinery for constructive rather than destructive ends.

Along the villous pathway, the evidence reveals a striking rise-and-fall pattern. Pioneering work by C. Coutifaris and colleagues showed that E-cadherin accumulates on the surfaces of cytotrophoblasts at points of cell-cell contact, peaking around twenty-four hours as cells aggregate into clusters. But once fusion begins, E-cadherin must disappear. Follow-up studies demonstrated that its loss is a requirement, not merely a consequence, of trophoblast fusion: high levels physically aggregate the mononuclear cells, and only their dynamic downregulation allows adjacent membranes to dissolve so cytoplasm can merge. In BeWo cell models treated with cAMP analogs or forskolin, fusion coincided with E-cadherin vanishing from cell surfaces, and the transcription factor Twist, which localizes to syncytiotrophoblast nuclei, was shown to repress the protein during this transition.

The review highlights three converging mechanisms that drive E-cadherin down during syncytialization. First, transcriptional repression by Twist, and possibly Snail, silences CDH1 expression. Second, enzymes do the cutting: HtrA4, a protease highly expressed in the placenta, is essential, because when it is silenced or deleted, E-cadherin persists and fusion is completely blocked. ADAM12, a member of the disintegrin and metalloprotease family, potentiates fusion by shedding the E-cadherin ectodomain, destabilizing existing adherens junctions and catalyzing membrane coalescence. Third, and perhaps most surprisingly, physics joins in. Mechanical stress patterns predicted by computational models of villous morphogenesis, when applied to cytotrophoblast monolayers, were shown to facilitate E-cadherin downregulation, with equibiaxial compressive stresses potentially lowering the energetic barrier for membrane fusion by rearranging lipids and proteins at the fusion interface.

Along the extravillous pathway, E-cadherin plays an equally dramatic but opposite-seeming role. Its transient downregulation characterizes a physiological epithelial-to-mesenchymal transition that permits trophoblasts to detach from anchoring columns and invade the decidua. The functional evidence is compelling: when researchers experimentally restored E-cadherin in invasive trophoblasts, the cells lost their migratory shapes, reverted to cohesive aggregates, and exhibited robust contact-dependent inhibition of movement. Repressors such as Twist, Snail, ZEB1 and ZEB2 correlate inversely with E-cadherin in these cells, and the concurrent upregulation of N-cadherin actively promotes the disassembly of E-cadherin-mediated adhesions. Yet the story does not end with invasion. When trophoblasts reach the spiral arteries, E-cadherin expression rises again, cooperating with VE-cadherin and VCAM-1 in a form of vascular mimicry that lets the cells withstand hemodynamic forces and integrate into the vessel wall. This partial reversal of EMT suggests that E-cadherin loss is a transient state, not a terminal commitment.

The clinical stakes are considerable. Persistent E-cadherin expression on the syncytiotrophoblast layer signals incomplete fusion, and its abnormal persistence correlates with preeclampsia and fetal growth restriction, conditions linked to poorly formed syncytium and shallow trophoblast invasion. The review proposes that soluble E-cadherin fragments shed by ADAM12 might be detectable in maternal blood during the first trimester, offering a potential early biomarker of defective placentation, though large-scale translational studies are needed to establish feasibility. Histologically, the disappearance of E-cadherin-stained cell boundaries already serves as a reliable indicator of successful syncytial maturation, and quantifying E-cadherin levels provides a valid, if complementary, experimental metric of fusion efficiency.

What excites the field most, however, is what remains unknown. The authors argue that research must now move from descriptive profiling to functional mechanism. Key questions include whether HtrA4, ADAM12 and compressive forces operate in a linear cascade or parallel networks, whether mechanosensitive channels such as PIEZO1 translate mechanical strain into the intracellular cAMP signals that initiate fusion, and how the intracellular pool of E-cadherin is cleared through endocytosis, proteasomal or lysosomal degradation. Whether trophoblast-derived soluble E-cadherin fragments act as signaling molecules, as they do in cancer, or as decoys disrupting maternal junctions is unexplored. The reviewers call for spatial transcriptomics, single-cell RNA sequencing, atomic force microscopy and advanced membrane imaging to map how tissue stiffness, fluid shear stress and local immune cells, including uterine natural killer cells, trigger the E-cadherin switch cell by cell. If those efforts succeed, a protein once known only as epithelial glue may emerge as both a diagnostic window into pregnancy complications and a therapeutic target in placental disease.

Subject of Research: The role of spatio-temporal E-cadherin expression in regulating trophoblast lineage differentiation during human placentation

Article Title: Spatio-temporal expression of E-cadherin mediates trophoblast lineage transitions during human placentation

Article References: Adu-Gyamfi, E. A., & Backes, E. (2026). Spatio-temporal expression of E-cadherin mediates trophoblast lineage transitions during human placentation. Molecular Biology Reports, 53(1), Article 1678. https://doi.org/10.1007/s11033-026-12837-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12837-0

Keywords: E-cadherin, trophoblast, placentation, syncytiotrophoblast, extravillous trophoblast, epithelial-to-mesenchymal transition, preeclampsia, fetal growth restriction, spiral artery remodeling, HtrA4, ADAM12, mechanobiology

The research, led by Xinjun Li and Shengpu Wang with colleagues at hospitals affiliated with Hebei Medical University, began not at the laboratory bench but in public data repositories. The team mined two transcriptome datasets, GSE114691 and GSE24129, from the Gene Expression Omnibus, comparing gene activity in placental samples from pregnancies affected by fetal growth restriction against normal controls. The comparison revealed a striking molecular signature: 5,788 genes were differentially expressed between the two groups, with 1,450 switched to higher activity and 4,338 dialed down. That scale of disruption, affecting thousands of genes at once, underscores how profoundly the placental environment is altered when fetal growth falters, and it also illustrates why single-gene studies have struggled to untangle the condition’s causes.

To make sense of this flood of data, the researchers turned to functional enrichment analysis, a computational method that groups genes by the biological processes they participate in. The picture that emerged was coherent and biologically telling. The genes that were downregulated in growth-restricted placentas clustered around mitochondrial function, aerobic respiration, and amino acid metabolism, pointing to an energy crisis within placental tissue. In other words, the cellular power plants of the placenta appear to be running at reduced capacity, and the metabolic machinery that processes amino acids, the raw material for building fetal tissue, is similarly blunted. Meanwhile, the upregulated genes were associated with cell adhesion and histone modification, hinting at altered cell-to-cell architecture and changes in how DNA is packaged and read inside placental cells.

Identifying thousands of dysregulated genes is one thing; finding the handful that truly matter is another. To narrow the field, the team applied weighted gene co-expression network analysis, or WGCNA, a technique that organizes genes into modules based on patterns of coordinated activity across samples. The analysis produced 19 such modules, and one of them, labeled the darkorange module, showed the strongest positive correlation with fetal growth restriction. Genes in this module rose and fell together in ways that tracked the disease state, marking it as the most promising region of the transcriptomic landscape for further interrogation.

From that module, the researchers deployed LASSO regression, a statistical method that penalizes complexity and is widely used to distill large panels of candidate predictors down to a compact, robust set. The procedure selected eight candidate genes. The team then tested each against an independent validation dataset, looking for a gene whose behavior held up outside the data in which it was originally found. Only one passed that test cleanly: TRIP10, which showed consistent and significant upregulation in the validation set. Just as importantly, TRIP10 demonstrated excellent diagnostic performance, achieving an area under the curve of 0.906, a value close to 1.0 that indicates the gene’s expression levels separate growth-restricted placentas from healthy ones with high accuracy.

Computational findings in genomics are notoriously fragile, so the team moved to confirm the result at the protein level. Using Western blot analysis, a laboratory technique that detects specific proteins in tissue samples, they found that TRIP10 protein was significantly elevated in placental tissues from fetal growth restriction cases, matching the RNA-level signal. This convergence of transcriptomic and proteomic evidence is critical, because genes that are transcribed more abundantly do not always yield more protein, and it is protein, ultimately, that does the work of the cell. With both lines of evidence aligned, TRIP10 moved from statistical curiosity to credible biological suspect.

The next question was what TRIP10 actually does, and here the researchers turned to JEG-3 cells, a widely used laboratory model of human trophoblasts, the specialized cells that form the placenta’s interface with the mother. In a healthy pregnancy, trophoblasts must migrate and invade into the uterine wall, remodeling maternal blood vessels to secure an adequate blood supply for the fetus. When that invasion is shallow or incomplete, the placenta cannot deliver sufficient oxygen and nutrients, and fetal growth suffers. The team manipulated TRIP10 expression in these cells in both directions and measured the consequences. When they knocked TRIP10 down, cell migration and invasion were significantly enhanced. When they overexpressed the gene, those processes were suppressed. The results establish TRIP10 as a negative regulator of trophoblast migration and invasion, precisely the functions that are impaired in fetal growth restriction.

The biology of TRIP10 makes this finding especially intriguing. The gene encodes a protein involved in regulating Cdc42, a master molecular switch that governs cell polarity, shape, and movement, and it has been implicated in the formation of cellular junctions and in signalosome complexes in other tissues. A gene that controls the cytoskeletal machinery of cell movement, when overactive in the placenta, would be expected to restrain exactly the invasive behavior that trophoblasts need to perform. The new data suggest that TRIP10 dysregulation may contribute to impaired placental development, providing a mechanistic link between a single gene and a whole-pregnancy disorder. The downregulated metabolic pathways seen in the enrichment analysis may represent downstream consequences of a placenta that never properly established itself in the first place.

The clinical implications are twofold. First, TRIP10’s strong diagnostic performance raises the possibility of a molecular test to complement the ultrasound-based biometric measurements that currently define the standard of care. Screening for fetal growth restriction remains imperfect, and the condition is frequently underdiagnosed, so biomarkers that flag at-risk pregnancies earlier could allow closer surveillance and better-timed delivery decisions. Second, if TRIP10’s suppression of trophoblast invasion is confirmed as a causal driver rather than a bystander effect, it opens a path toward therapies aimed at restoring normal trophoblast behavior. That prospect remains distant, as the current evidence comes from a cell line and placental tissue rather than animal models or clinical trials, but it gives researchers a concrete molecular handle on a process that has been almost entirely opaque.

The study, supported by the Medical Science Research Project of Hebei and approved by the ethics committee of the Fourth Hospital of Hebei Medical University, exemplifies a workflow that is becoming the gold standard in translational genomics: mine public datasets, use network analysis and machine learning to distill candidates, validate in independent cohorts, and then confirm function experimentally. By following that path, the team has taken TRIP10 from an anonymous entry in a gene expression matrix to a named suspect in one of obstetrics’ most consequential mysteries. Larger studies across diverse populations will be needed to confirm the gene’s diagnostic value and to clarify whether it drives fetal growth restriction or merely marks it, but the finding offers something the field has lacked: a specific, testable molecular target in the placenta, and a reason to believe that the roots of fetal growth restriction may be within reach of both earlier detection and, eventually, intervention.

Subject of Research: Identification of the gene TRIP10 as a dysregulated regulator of trophoblast function in fetal growth restriction

Article Title: TRIP10 as a Key Regulator in Fetal Growth Restriction: a Study Integrating Bioinformatics Screening with Experimental Validation

Article References: Li, X., Xu, S., Zhang, X., Lian, W., Liu, G., & Wang, S. (2026). TRIP10 as a Key Regulator in Fetal Growth Restriction: a Study Integrating Bioinformatics Screening with Experimental Validation. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02222-4

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02222-4

Keywords: fetal growth restriction, TRIP10, placenta, trophoblast, bioinformatics, WGCNA, LASSO regression, gene expression, biomarker, cell migration, Reproductive Sciences, placental development

The new study, published as an open-access original article in Cellular and Molecular Life Sciences, focuses on a chemical tag known as N6-methyladenosine, or m6A, the most abundant internal modification found in messenger RNA molecules across eukaryotic cells. Far from being decorative, m6A marks act as a dynamic layer of gene regulation: they influence how efficiently a transcript is translated into protein, how long it survives before being degraded, and even where it localizes within the cell. Writers install the mark, readers interpret it, and erasers remove it. The enzyme at the heart of the new findings, alkylation repair homolog protein 5, better known as ALKBH5, belongs to this last category. It is a demethylase, an enzyme that chemically strips m6A marks from RNA, and previous work had implicated it in everything from spermatogenesis to cancer progression. Whether it played any role in the diseased placenta, however, was unknown.

To find out, the researchers began where the disease begins: in placental tissue. Analyzing clinical samples from patients with preeclampsia, they discovered that ALKBH5 was consistently upregulated in the placentas of affected mothers compared with healthy pregnancies. Crucially, this overabundance of the demethylase coincided with a global decrease in m6A levels across placental transcripts, exactly what one would expect if an RNA eraser were working overtime. The same pattern appeared in a mouse model of preeclampsia-like disease, strengthening the case that the observation was not a human-tissue artifact but a reproducible feature of the disorder. The correlation, while compelling, left open the central question of causation: was ALKBH5 merely a bystander in the stressed placenta, or was it actively driving the pathology?

The team turned to a laboratory workhorse to answer that question. HTR8/SVneo cells, an immortalized human trophoblast line widely used to model placental cell behavior, were exposed to hydrogen peroxide to induce oxidative stress, mimicking the hostile environment that trophoblasts face in a preeclamptic placenta. As anticipated, the stressed cells lost their ability to invade and migrate, the very functions that healthy trophoblasts must perform to anchor the placenta and remodel maternal spiral arteries. But when the researchers knocked down ALKBH5 using small interfering RNA, the damage was partially reversed. The treated cells recovered a significant portion of their invasive and migratory capacity, suggesting that ALKBH5 was not simply responding to stress but actively contributing to the functional collapse of trophoblasts under oxidative assault.

With a functional link established, the next challenge was to identify the molecular target through which ALKBH5 exerted its effects. The researchers performed an integrated bioinformatics analysis, cross-referencing the RM2Target database with Gene Expression Omnibus datasets to search for genes that were both regulated by ALKBH5 and relevant to trophoblast biology. The search converged on a single compelling candidate: formyl peptide receptor 2, or FPR2, a G-protein-coupled receptor known to participate in inflammatory signaling. Subsequent validation experiments, including RNA immunoprecipitation and dual-luciferase reporter assays, confirmed that ALKBH5 physically and functionally interacts with FPR2 messenger RNA, establishing FPR2 as a bona fide downstream target of the demethylase.

The mechanistic details that emerged are elegant and, in the context of pregnancy disease, genuinely novel. ALKBH5 binds to the 3′ untranslated region of the FPR2 transcript, the stretch of RNA that follows the protein-coding sequence and typically governs transcript stability. By erasing m6A marks at this location, ALKBH5 stabilizes the FPR2 mRNA, allowing it to persist longer in the cell and driving up the production of the FPR2 receptor protein. In other words, the demethylase does not change the genetic message itself; it changes how long the message survives, and in doing so it amplifies a receptor that ultimately undermines trophoblast behavior. This m6A-dependent stabilization mechanism illustrates how epitranscriptomic regulation, a field barely two decades old, can produce consequences as dramatic as a pregnancy disorder.

The functional experiments sealed the argument. When the researchers overexpressed FPR2 in trophoblasts that had been protected by ALKBH5 knockdown, the protective effect vanished: the cells once again lost their invasive and migratory prowess under oxidative stress. FPR2, it appeared, was the executioner carrying out the damage that ALKBH5 had set in motion. Conversely, when the team administered WRW4, a pharmacological antagonist of FPR2, to mice with preeclampsia-like features, the disease phenotype improved. The antagonist ameliorated the key characteristics of the disorder in the animal model, providing proof of principle that blocking the receptor downstream of ALKBH5 can counteract the pathological process in a living system.

Taken together, the findings define what the authors describe as an ALKBH5–FPR2 axis in preeclampsia pathogenesis: an RNA-erasing enzyme upregulated in the diseased placenta strips methylation marks from FPR2 transcripts, prolongs their half-life, boosts receptor expression, and thereby disrupts the trophoblast functions on which a healthy pregnancy depends. The chain of evidence runs from human placental tissue through cell culture under oxidative stress to a mouse model and back again, with pharmacological rescue at the endpoint. Few studies of preeclampsia have traced a causal pathway with this degree of molecular resolution, and the identification of an epitranscriptomic mechanism in the disorder opens a fresh dimension in a field long dominated by angiogenic factors and immune hypotheses.

The therapeutic implications are tantalizing, though tempered by the usual caveats of early-stage research. Both nodes of the axis offer potential points of intervention: inhibiting ALKBH5 activity or blocking FPR2 signaling with agents such as WRW4 could, in theory, restore trophoblast function before the maternal syndrome takes hold. Because FPR2 already has known pharmacological modulators, the receptor represents a particularly attractive druggable target, and repurposing efforts could accelerate translation. Yet significant hurdles remain. The mouse model recapitulates preeclampsia-like features but not the full human disease, the precise timing and cell types in which the axis operates during human placentation require further mapping, and any intervention in pregnancy demands an exceptionally high safety bar. Still, the study adds a powerful new concept to the preeclampsia literature: that the fate of a pregnancy may hinge not on which genes are present, but on how long their RNA messages endure. As m6A biology continues to reshape our understanding of human disease, the placenta has now joined the list of organs where the epitranscriptome writes, and erases, the story of health.

Subject of Research: The role of the m6A demethylase ALKBH5 and its downstream target FPR2 in the pathogenesis of preeclampsia

Article Title: ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2

Article References: Fan, C., Zhang, C., Liu, L., & Zhang, M. (2026). ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06471-z

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06471-z

Keywords: preeclampsia, ALKBH5, FPR2, m6A, RNA methylation, epitranscriptomics, trophoblast, placenta, oxidative stress, RNA stability, pregnancy, molecular biology

7-ketocholesterol is one of the most abundant cholesterol oxidation products in the human body. It arises when free cholesterol encounters oxidative stress, a condition in which reactive oxygen species overwhelm cellular antioxidant defenses. Because pregnancy itself is a state of controlled oxidative stress, and because conditions such as preeclampsia, gestational diabetes, and maternal hypercholesterolemia amplify that stress dramatically, the placenta represents a uniquely vulnerable environment for oxysterol accumulation. The review synthesizes evidence on where 7-ketocholesterol comes from, how it travels through the placenta, and what it does once it arrives.

The sources of this molecule are more varied than many clinicians realize. Endogenously, 7-ketocholesterol forms whenever cholesterol-rich membranes and lipoproteins are exposed to oxidative attack, which can happen in the maternal circulation, in placental tissue, and even in the fetal compartment. Exogenously, it enters the body through the diet: cholesterol-containing foods such as processed meats, eggs, and dairy products generate cholesterol oxidation products during cooking, storage, and reheating, and these dietary oxysterols are readily absorbed. Maternal hypercholesterolemia raises the substrate pool for oxysterol formation, and studies in animal models have shown that mothers with elevated cholesterol carry higher oxysterol concentrations, as do their newly weaned offspring, an effect that can be blunted by maternal phytosterol supplementation.

Once formed, 7-ketocholesterol does not stay put. The placenta is a lipid trafficking hub, actively transferring cholesterol from mother to fetus to support the enormous demands of fetal growth, membrane synthesis, and steroid hormone production. This transfer relies on a coordinated cast of transporters and enzymes, including ABCA1 and ABCG1, which efflux cholesterol from trophoblasts, and placental endothelial cells that deliver cholesterol efficiently into the fetal circulation. The critical question raised by the review is whether oxidized cholesterol derivatives piggyback on these same pathways. If 7-ketocholesterol crosses the placental barrier alongside native cholesterol, it could expose fetal tissues to a molecule known to be cytotoxic at relatively low concentrations.

What happens when trophoblasts, the workhorse cells of the placenta, encounter oxysterols? Experimental work offers troubling clues. Studies of term primary trophoblasts have shown that oxysterols inhibit the differentiation and fusion of these cells by activating liver X receptors, a family of nuclear receptors that regulate lipid metabolism. Trophoblast fusion is essential for forming the syncytiotrophoblast, the multinucleated layer that performs nutrient exchange and hormone secretion, so any interference with this process could compromise placental capacity. Oxysterols also exert proinflammatory effects in trophoblasts through Toll-like receptor 4-dependent, cholesterol-sensitive activation of NF-κB, igniting inflammatory signaling cascades within the very cells that anchor the pregnancy.

The cellular damage does not stop there. 7-ketocholesterol is notorious for disrupting mitochondrial function, promoting lysosomal dysfunction, and triggering autophagic markers such as light chain 3 processing and protein ubiquitination in vascular cells. Its polar chemical nature means it lodges preferentially within membrane domains, including lipid rafts, altering membrane order and biophysical properties in ways that can flip cellular signaling from survival toward death. In fetoplacental endothelial cells, oxysterol exposure induces inflammatory responses and dysfunction, although activation of liver X receptors has been shown to attenuate some of this damage, hinting at a possible therapeutic lever. Placental ABCA1 and ABCG1 transporters appear to protect trophoblasts by effluxing cholesterol and oxysterols, and increased cholesterol efflux capacity has been observed in preeclampsia, possibly reflecting a compensatory response to lipid stress.

Metabolism of 7-ketocholesterol is another piece of the puzzle. Outside the liver, the molecule is handled by esterification to fatty acids via the enzymes cPLA2α and SOAT1, followed by selective efflux to high-density lipoprotein. Whether the placenta possesses sufficient capacity to detoxify 7-ketocholesterol by these routes remains an open question, and the review highlights this as a key knowledge gap. Enzymes such as placental CYP27A1, which is upregulated in preeclampsia, may also participate in oxysterol handling, suggesting that the placenta actively attempts to manage oxidized sterols even under pathological conditions.

The most provocative framing in the review connects 7-ketocholesterol to the Developmental Origins of Health and Disease, or DOHaD, framework. This paradigm holds that adverse conditions in the womb, from poor nutrition to oxidative stress, can program lasting changes in offspring metabolism, cardiovascular function, and disease risk. Oxidative stress is known to drive epigenetic modifications, including DNA methylation changes, and early pregnancy dyslipidemia has been associated with placental DNA methylation at loci relevant to cardiometabolic disease. If 7-ketocholesterol contributes to the oxidative and inflammatory milieu of a stressed placenta, it could serve as a concrete molecular mediator linking maternal lipid disturbances to fetal programming, potentially influencing offspring risks ranging from obesity and metabolic syndrome to neurodevelopmental conditions.

Epidemiological signals lend circumstantial support to this idea. Maternal cholesterol levels have been linked in birth cohort studies to offspring attention deficit hyperactivity disorder, with apparent sex differences, and maternal metabolic profiles in early pregnancy correlate with offspring adiposity in childhood. Maternal intrahepatic cholestasis of pregnancy, a disorder of bile acid and lipid handling, has been associated with neurodevelopmental conditions in a population-based cohort of two million Swedish children. A pilot study has even reported associations between maternal mid-pregnancy cholesterol and oxysterol concentrations and labor duration. None of these findings proves causation for 7-ketocholesterol specifically, but together they sketch a pattern in which maternal lipid biology leaves measurable fingerprints on fetal development.

The authors are careful to frame their work as a call to arms rather than a settled verdict. Direct measurements of 7-ketocholesterol in human placental tissue, cord blood, and fetal circulation remain scarce, and much of the mechanistic evidence comes from cell culture and animal studies using related oxysterols. Analytical challenges, including the instability of oxysterols and the technical demands of mass spectrometry-based measurement, have likely slowed progress. The review points toward several priorities: quantifying 7-ketocholesterol across normal and complicated pregnancies, mapping its placental transport and metabolism, testing whether dietary and antioxidant interventions can lower maternal oxysterol burden, and exploring whether liver X receptor activation or other protective pathways can shield the fetoplacental unit. If future studies confirm the review’s central hypothesis, a molecule forged from ordinary cholesterol by ordinary oxidative wear could become an unexpected target for protecting both pregnancies and the lifelong health of the children they produce.

Subject of Research: The role of the oxysterol 7-ketocholesterol in placental pathophysiology, fetal programming, and long-term offspring health

Article Title: The Role of 7-ketocholesterol in Placental Pathophysiology: Implications for Fetal Programming and Long-term Health: A Narrative Review

Article References: Ganamurali, N., & Sabarathinam, S. (2026). The Role of 7-ketocholesterol in Placental Pathophysiology: Implications for Fetal Programming and Long-term Health: A Narrative Review. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02207-3

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02207-3

Keywords: 7-ketocholesterol, placenta, oxysterols, oxidative stress, fetal programming, pregnancy, trophoblast, cholesterol transport, epigenetics, DOHaD, preeclampsia, maternal hypercholesterolemia